07.02.2022 - PRESS RELEASE AB SCIENCE TO PRESENT ON ITS AMYOTROPHIC LATERAL SCLEROSIS (ALS) DEVELOPMENT PROGRAM AT THE 2022 ALS DRUG DEVELOPMENT SUMMIT Paris, 07 February, 2022, 6pm CET AB Science SA (Euronext - FR0010557264 - AB) today announced that . Seite 1
Press release content from Globe Newswire. The AP news staff was not involved in its creation.
AB Science announces that a new independent publication confirms that masitinib has anti-vital .
AB ScienceJanuary 25, 2021 GMT
NEW INDEPENDENT PUBLICATION CONFIRMS THAT MASITINIB HAS ANTI-VIRAL ACTIVITY AGAINST THE SARS-COV-2 VIRUS
IN VITRO AND IS A PROMISING CANDIDATE FOR TREATING COVID-19
Paris, 25 January 2021, 8.30am CET
AB Science SA (NYSE Euronext - FR0010557264 - AB) today announced the publication of preclinical study results with masitinib in COVID-19. Research led by scientists from the Institute of Human Virology (Guangzhou, China) has been published in the peer-reviewed journal
mBIO (a journal of the American Society for Microbiology). The article, entitled ‘Engineering a reliable and convenient SARS-CoV-2 replicon system for analysis of viral RNA synthesis and screening of antiviral inhibitors’,[1] is freely accessible online from the mBio journal site https://mb